Cravath’s New York Office Moves to Two Manhattan West
July 11, 2024
On July 9, 2024, the Committee on Patents of the New York City Bar Association (“Patents Committee”) submitted comments on the proposed amendment from the U.S. Patent and Trademark Office (“USPTO”) to its terminal disclaimer rules, co‑authored by Cravath partner and Patents Committee Chair Sharonmoyee Goswami. The comments discuss the potential implications of the proposed amendment, which would require patent applicants to agree that a patent subject to a terminal disclaimer would be unenforceable if any claim of a patent tied by the terminal disclaimer is found invalid as anticipated or obvious.
Deals & Cases
January 31, 2023
In January, 2023, Cravath client Abiomed Inc. (“Abiomed”) secured a victory before the U.S. Patent Trial and Appeal Board (“PTAB”) of the United States Patent and Trademark Office (“USPTO”).
Deals & Cases
September 02, 2022
On September 1, 2022, Chief Administrative Law Judge D. Michael Chappell of the Federal Trade Commission (“FTC”) ruled in favor of Cravath client Illumina, rejecting the FTC’s challenge to Illumina’s $8 billion acquisition of GRAIL, which closed in August 2021.
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2024 Cravath, Swaine & Moore LLP.